In New York on July 30, 2026, Cellectis, a leading clinical-stage biotech firm utilizing innovative gene-editing technology, disclosed plans to release its financial report for the second quarter of 2026 that concluded on June 30, 2026. The report will be made public on Thursday, August 6, 2026, following the closure of the US market. Cellectis is traded on Euronext Growth under the symbol ALCLS and on NASDAQ under the symbol CLLS.